Dr. Iruela-Arispe on the Dr. Paul Janssen Award Symposium

Luisa Iruela-Arispe, PhD
Published: Thursday, Oct 13, 2011

Luisa Iruela-Arispe, PhD, director, JCCC Cancer and Stem Cell Biology Program Area, professor and vice chair, Molecular, Cell, and Developmental Biology, University of California, Los Angeles (UCLA), discusses the highlights from the 2011 Dr. Paul Janssen Award Symposium, Wednesday, September 14, 2011, in New York City, NY.

The symposium highlighted the benefits of single agent bevacizumab (Avastin) and awarded the 2011 Dr. Paul Janssen Award for Biomedical Research to Napoleone Ferrara, MD, the discoverer of the vascular endothelial growth factor (VEGF) angiogenic-signaling molecule.

Angiogenesis breakthroughs and therapeutic applications were the focus of the one-day symposium; it focused specifically on bevacizumab and its impact on multiple individual lives. The need to work across multiple disciplines to enhance the drugs efficacy and possible combinations with other targeted therapeutics was the main topic of discussion.

Luisa Iruela-Arispe, PhD, director, JCCC Cancer and Stem Cell Biology Program Area, professor and vice chair, Molecular, Cell, and Developmental Biology, University of California, Los Angeles (UCLA), discusses the highlights from the 2011 Dr. Paul Janssen Award Symposium, Wednesday, September 14, 2011, in New York City, NY.

The symposium highlighted the benefits of single agent bevacizumab (Avastin) and awarded the 2011 Dr. Paul Janssen Award for Biomedical Research to Napoleone Ferrara, MD, the discoverer of the vascular endothelial growth factor (VEGF) angiogenic-signaling molecule.

Angiogenesis breakthroughs and therapeutic applications were the focus of the one-day symposium; it focused specifically on bevacizumab and its impact on multiple individual lives. The need to work across multiple disciplines to enhance the drugs efficacy and possible combinations with other targeted therapeutics was the main topic of discussion.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x